As Humira sales fall, AbbVie focuses on Skyrizi, Rinvoq growth, eyes external combo strategies 

Ab­b­Vie said Hu­mi­ra, one of the world’s biggest-sell­ing drugs, still brought in $3.5 bil­lion in sales in the third quar­ter, though the 36% dip in year-over-year rev­enue was in line with Wall Street pro­jec­tions now that rough­ly 10 biosim­i­lars have en­tered the mar­ket.

In its third-quar­ter earn­ings call on Fri­day, the phar­ma gi­ant em­pha­sized the per­for­mance of its next-gen­er­a­tion im­munol­o­gy drugs, Rin­voq and Skyrizi, cit­ing their growth as the com­pa­ny raised its full-year rev­enue guid­ance by $600 mil­lion on Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.